Novo Nordisk A/S, Ventas, Blackstone, SpringWorks Therapeutics, and Apollo Global Management are the five Growth stocks to watch today, according to MarketBeat's stock screener tool. Error: Response status code does not indicate success: 429 (Too Many Requests). These companies had the highest dollar trading volume of any Growth stocks within the last several days.
Novo Nordisk A/S (NVO)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
Novo Nordisk A/S stock traded down $0.89 during trading hours on Thursday, reaching $65.56. 11,529,826 shares of the stock were exchanged, compared to its average volume of 6,173,983. The stock has a market cap of $294.20 billion, a P/E ratio of 19.90, a P/E/G ratio of 0.90 and a beta of 0.61. The firm's 50 day moving average is $72.40 and its 200 day moving average is $88.69. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. Novo Nordisk A/S has a 52-week low of $57.00 and a 52-week high of $148.15.
Read Our Latest Research Report on NVO
Ventas (VTR)
Ventas Inc. NYSE: VTR is a leading S&P 500 real estate investment trust focused on delivering strong, sustainable shareholder returns by enabling exceptional environments that benefit a large and growing aging population. The Company's growth is fueled by its senior housing communities, which provide valuable services to residents and enable them to thrive in supported environments.
NYSE VTR traded down $4.23 during trading hours on Thursday, hitting $65.85. 4,516,927 shares of the stock were exchanged, compared to its average volume of 2,693,757. Ventas has a 12-month low of $43.64 and a 12-month high of $71.36. The stock has a 50-day moving average of $67.70 and a 200 day moving average of $63.92. The company has a market cap of $28.82 billion, a price-to-earnings ratio of 344.39, a price-to-earnings-growth ratio of 2.59 and a beta of 1.02. The company has a quick ratio of 0.85, a current ratio of 0.85 and a debt-to-equity ratio of 1.25.
Read Our Latest Research Report on VTR
Blackstone (BX)
Blackstone Inc. is an alternative asset management firm specializing in real estate, private equity, hedge fund solutions, credit, secondary funds of funds, public debt and equity and multi-asset class strategies. The firm typically invests in early-stage companies. It also provide capital markets services.
Shares of BX traded up $2.57 during mid-day trading on Thursday, hitting $134.28. The company's stock had a trading volume of 2,046,633 shares, compared to its average volume of 3,762,664. The firm has a 50-day simple moving average of $139.76 and a 200 day simple moving average of $163.62. Blackstone has a 1-year low of $115.66 and a 1-year high of $200.96. The firm has a market capitalization of $97.94 billion, a P/E ratio of 36.99, a P/E/G ratio of 1.07 and a beta of 1.61. The company has a current ratio of 0.67, a quick ratio of 0.71 and a debt-to-equity ratio of 0.61.
Read Our Latest Research Report on BX
SpringWorks Therapeutics (SWTX)
SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.
Shares of NASDAQ SWTX traded down $0.06 during trading on Thursday, hitting $46.25. 4,426,489 shares of the company were exchanged, compared to its average volume of 1,885,492. The firm's fifty day moving average price is $45.49 and its 200 day moving average price is $40.82. The company has a market cap of $3.47 billion, a price-to-earnings ratio of -13.29 and a beta of 0.79. SpringWorks Therapeutics has a 1 year low of $28.21 and a 1 year high of $62.00.
Read Our Latest Research Report on SWTX
Apollo Global Management (APO)
Apollo Global Management, Inc. is a private equity firm specializing in investments in credit, private equity, infrastructure, secondaries and real estate markets. The firm prefers to invest in private and public markets. The firm's private equity investments include traditional buyouts, recapitalization, distressed buyouts and debt investments in real estate, corporate partner buyouts, distressed asset, corporate carve-outs, middle market, growth, venture capital, turnaround, bridge, corporate restructuring, special situation, acquisition, and industry consolidation transactions.
APO stock traded up $2.89 during trading on Thursday, reaching $139.37. 1,457,257 shares of the company were exchanged, compared to its average volume of 3,831,923. The stock's 50 day moving average price is $133.57 and its 200 day moving average price is $152.99. Apollo Global Management has a 52-week low of $95.11 and a 52-week high of $189.49. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.44 and a current ratio of 1.44. The company has a market cap of $79.51 billion, a P/E ratio of 19.05, a PEG ratio of 1.17 and a beta of 1.66.
Read Our Latest Research Report on APO
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Novo Nordisk A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novo Nordisk A/S wasn't on the list.
While Novo Nordisk A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
